Condition
Pelvic Radiotherapy
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Not Yet Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07216456Not ApplicableNot Yet RecruitingPrimary
Vaginal Dilator Therapy After Pelvic Radiation
NCT06783153Phase 1Not Yet Recruiting
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
NCT03714581Not ApplicableUnknownPrimary
Laser Therapy Following Radiotherapy for Gynecological Cancer
Showing all 3 trials